Percheron Therapeutics Ltd
ASX:PER
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Percheron Therapeutics Ltd
Depreciation & Amortization
Percheron Therapeutics Ltd
Depreciation & Amortization Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Depreciation & Amortization | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Percheron Therapeutics Ltd
ASX:PER
|
Depreciation & Amortization
-AU$51k
|
CAGR 3-Years
18%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
|
Recce Pharmaceuticals Ltd
ASX:RCE
|
Depreciation & Amortization
-AU$336.7k
|
CAGR 3-Years
-30%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Depreciation & Amortization
-AU$61m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Depreciation & Amortization
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
Depreciation & Amortization
-AU$185.1k
|
CAGR 3-Years
-59%
|
CAGR 5-Years
-61%
|
CAGR 10-Years
N/A
|
|
|
Nyrada Inc
ASX:NYR
|
Depreciation & Amortization
-AU$3.2k
|
CAGR 3-Years
21%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
Percheron Therapeutics Ltd
Glance View
Percheron Therapeutics Ltd is a AU-based company operating in Pharmaceuticals industry. The company is headquartered in Melbourne, Victoria. The company went IPO on 2001-12-20. Percheron Therapeutics Limited, formerly Antisense Therapeutics Limited, is a biotechnology company. The firm is engaged in developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The Company’s products include ATL1102 for Duchenne muscular dystrophy (DMD), ATL1103 for Acromegaly, and ATL1102 for Multiple Sclerosis (MS). ATL1102, is an antisense inhibitor targeting very late antigen 4 (VLA-4), an immune cell molecule. ATL1103 is a second-generation antisense drug designed to block growth hormone receptor (GHr) expression thereby reducing levels of the hormone insulin-like growth factor-I (IGF-I) in the blood and is a potential treatment for diseases associated with excessive growth hormone action. By inhibiting GHr production, ATL1103 in turn reduces IGF-I levels in the blood (serum). The firm is conducting a Phase II clinical trial of ATL1102 in DMD patients.
See Also
What is Percheron Therapeutics Ltd's Depreciation & Amortization?
Depreciation & Amortization
-51k
AUD
Based on the financial report for Dec 31, 2025, Percheron Therapeutics Ltd's Depreciation & Amortization amounts to -51k AUD.
What is Percheron Therapeutics Ltd's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 5Y
15%
Over the last year, the Depreciation & Amortization growth was 25%. The average annual Depreciation & Amortization growth rates for Percheron Therapeutics Ltd have been 18% over the past three years , 15% over the past five years .
